This anti-tumorigenic property of MYC needs to be overcome for tumor development to occur, and mutations or deregulated expression of components of both the intrinsic and extrinsic pathways have been documented in AML [36], although the relative contribution of these pathways for the disease has not been investigated systematically. This evidence concerns the gene MYC and acute myeloid leukemia.